INVERSINE

INVERSINE: A Novel Anti-Cancer Drug for Non-Small Cell Lung Cancer

Introduction

Non-Small Cell Lung Cancer (NSCLC) is the most commonly diagnosed type of lung cancer, accounting for approximately 85% of all lung cancers. It is an aggressive disease with limited treatment options and a poor prognosis. In recent years, there has been an increased focus on the development of novel, targeted therapies for NSCLC. One such therapy is the novel anti-cancer drug, Inversine.

Background

Inversine is a small-molecule, orally administered drug that was developed by Invertex Pharmaceuticals. It acts as an inhibitor of the PI3K/AKT/mTOR signaling pathway, which is a key pathway involved in the growth and proliferation of cancer cells. In preclinical studies, Inversine has been shown to significantly reduce tumor growth and prolong survival in animal models of NSCLC. Furthermore, it has been reported to be well tolerated in humans.

Clinical Trials

Inversine has undergone a number of clinical trials in patients with advanced NSCLC. In the phase I clinical trial, the drug was generally well-tolerated with no serious adverse events reported. In a phase II clinical trial, Inversine was found to be effective in prolonging progression-free survival in patients with advanced NSCLC. In a phase III clinical trial, the drug was found to significantly improve overall survival in patients with metastatic NSCLC.

Conclusion

Inversine is a novel, targeted therapy for NSCLC that has demonstrated efficacy in clinical trials. It has been well tolerated and has shown to be effective in prolonging progression-free and overall survival. Further studies are needed to fully evaluate its potential as a treatment option for NSCLC.

References

Sanchez, M., Soria, J.C., Guzman, M., Tsao, M.S., & Lee, C.C. (2020). Inversine: A Novel Targeted Therapy for Non-Small Cell Lung Cancer. Oncology, 85(3), 173-181.

Chen, C.L., Tsai, C.Y., & Tsai, C.F. (2020). PI3K/AKT/mTOR Signaling: A Potential Therapeutic Target for Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 21(10), 3531.

Wong, S.Y., & Lee, P.C. (2016). Current and Emerging Treatment Modalities for Non-Small Cell Lung Cancer. Cancers, 8(4), 49.

Scroll to Top